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Abstract
Objective: PTC-specific analysis identified novel fusions involving RET, BRAF, NTRK1, NTRK3, AGK and ALK genes in 
adults and pediatric PTCs. Although many novel fusions are PTC-specific events and, therefore, are ideal for diagnosis 
purposes, validation across additional and larger patient cohorts is essential for introducing these potential diagnostic 
or prognostic biomarkers into the clinical practice. As most of the BRAF, NTRK3 and ALK fusions were initially found in 
pediatric PTC or in more aggressive thyroid carcinomas, and there is a great disparity across population, in this study, 
we screened a large set of adult-sporadic PTC cases for the most prevalent kinase fusion lately described in the TCGA.
Design and methods: The prevalence of the fusions was determined by RT-PCR in 71 classical PTC, 45 follicular variants 
of PTC (FVPTC), 19 follicular thyroid adenomas (FTAs) and 22 follicular thyroid carcinomas (FTCs).
Results: ETV6–NTRK3 was exclusively found in FVPTC, in both encapsulated and infiltrative variants, but was not found 
in FTAs and FTCs. STRN-ALK was found in both classical PTC and FVPTC. No AGK-BRAF fusion was identified in this 
series, endorsing that AGK–BRAF is a genetic event mainly associated with pediatric PTCs.
Conclusions: The identification of kinase fusions in thyroid carcinomas helps to expand our knowledge about the 
landscape of oncogenic alterations in PTC. As ETV6–NTRK3 and STRN–ALK are recurrent and not identified in benign 
lesions, they can certainly help with diagnosis of thyroid nodules. Further analysis is needed to define if they can also 
be useful for prognosis and guiding therapy.
Introduction
Chromosomal rearrangements, which cause the 
production of a functional fusion gene, were the first 
mechanism of oncogene activation discovered in human 
cancers in 1973, particularly in hematologic malignancies 
(1, 2). The first gene fusion found in malignant epithelial 
tumors was reported in 1987, when the DNA isolated 
from a primary papillary thyroid carcinoma (PTC) was 
successfully delivered to NIH3T3 cells through transfection 
(3). Cytogenetic and molecular findings demonstrated that 
the gene fusion occurred due to a paracentric inversion 
of chromosome 10, which juxtaposes the intracellular 
tyrosine kinase domain of the RET to the 5′ sequence of 
the CCDC6, which is expressed in thyroid follicular cells 
(3, 4, 5). This novel fusion transcript was named RET/PTC, 
as it encompasses the RET gene and was exclusively found 
in PTC (3).
The following decade was characterized by the 
discovery of several novel fusions involving RET gene 
in both sporadic and radiation-induced PTCs. RET/PTC 
represents the major group of gene fusions found in PTC, 
with RET/PTC1 and RET/PTC3 being the most prevalent 
isoforms (reviewed in (6, 7, 8)). Importantly, in vitro and 
in vivo analyses confirmed that RET/PTC fusions have a 
critical role in thyroid carcinogenesis (9, 10, 11).
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Recently, advances in genomic technologies have 
uncovered novel fusion genes in thyroid tumors. The 
Cancer Genome Atlas (TCGA) Pan-Cancer project has 
generated comprehensive multidimensional maps of the 
key genomic changes in 33 tumors types, including PTC. 
PTC-specific analysis not only confirmed the significance 
of known fusions (RET and NTRK1) but also identified 
novel fusions involving kinases that very likely play a role 
in thyroid cancer such as BRAF, NTRK3 and ALK (12).
Although thyroid cancer showed lower frequency 
of kinase fusions compared to other tumor types, a high 
percentage of these events were recurrent, confirming their 
role in the pathogenesis of thyroid carcinomas. Among 
the novel gene fusions, some isoforms involving BRAF, 
NTRK3 and ALK genes were acknowledged to play a role 
in the pathogenesis of pediatric PTC or more aggressive 
variants of PTC.
Regarding fusions involving the BRAF gene, 
AGK–BRAF was primarily described in post-Chernobyl 
radiation-induced thyroid tumors (13) and later identified 
as a recurrent event in sporadic pediatric PTC (14). 
Moreover, among the isoforms identified, AGK–BRAF was 
functionally characterized and showed to be able to induce 
MAPK activation and to increase cell proliferation and 
transformation in NIH3T3 or COS7 transfected cells (13).
ETV6-NTRK3 is the most common rearrangement 
found after any RET/PTC isoform in the TCGA (12). While 
its prevalence was very low (1%) in PTC from adults (12, 
15), it is the second most common rearrangement in 
radiation-exposed PTC (13, 15). Additionally, ETV6-NTRK3 
has been shown to be able to induce MAPK activation 
and increase cell proliferation and transformation (13). 
Although other novel isoforms of NTRK3 fusions were 
described, only one sample was found to be positive for 
the NTRK3 fusion and the transforming potentials of 
these fusion proteins were not determined.
Finally, concerning ALK fusions, STRN–ALK was 
found as a very rare event identified in more aggressive 
variants of thyroid cancer (16) and in conventional PTCs 
(17). Importantly, its ectopic expression was able to 
induce MAPK activation, increase cell proliferation and 
transformation and induce tumor formation in xenograft 
models (16). Although novel ALK fusion variants were 
described in PTC, the isoforms were not found to be 
recurrent or were not functionally characterized.
Unlike RET/PTC, these fusions were not found in 
adjacent normal thyroid tissues or benign neoplasms 
(12, 13, 16, 17), which support the pathogenic role of 
these fusions in PTC.
As genetic and environmental variations contribute 
to population-based disparities and we enter the era 
of precision medicine and molecular diagnosis, we 
questioned about the implications of these novel fusions 
in the diagnosis of PTC from different geographical 
areas. Additionally, validation analysis in a large and 
independent set of malignant and benign lesions is 
indubitably essential to better define the relevance of 
these novel fusions in the pathogenesis of thyroid tumors 
and, consequently, in the differential diagnosis of thyroid 
nodules.
We here reported the prevalence of ETV6-NTRK3, 
STRN–ALK and AGK–BRAF fusions in a large Brazilian 
cohort of adult-sporadic PTC. We additionally assessed 
the prevalence of these fusions in other benign and 
malignant thyroid tumors.
Methods
Sample selection
The series consists of primary tumors from patients who 
underwent thyroid surgery from 2000 to 2007 at Hospital 
São Paulo, Universidade Federal de São Paulo and Hospital 
das Clínicas, Faculdade de Medicina da Universidade de 
São Paulo. The study included 116 PTCs, 71 (61%) classical 
PTCs and 45 (39%) follicular variants of papillary thyroid 
carcinoma (FVPTC). The final histological classification 
on surgical specimens was obtained from formalin-fixed 
paraffin-embedded sections. The FVPTC is defined as a 
tumor composed entirely or almost entirely of cells with 
a follicular architecture exhibiting nuclear features of 
classical PTC. The FVPTC can be completely encapsulated 
(EFVPTC) or partially encapsulated or infiltrative (IFVPTC). 
Additionally, 19 follicular thyroid adenomas (FTAs) and 
22 follicular thyroid carcinomas (FTCs) were used to 
investigate the presence of ETV6–NTRK3, STRN–ALK and 
AGK–BRAF in other benign and malignant thyroid tumor 
subtypes. None of the patients had a history of previous 
radiation exposure. Informed consent was obtained 
from all subjects involved in this study. The study was 
conducted under the approval of the Review Boards and 
Research Ethical Committees of the affiliated institutions. 
The demographic and clinico–pathological features such 
as the age at onset, gender, tumor size, histological variant, 
multifocality, extrathyroidal invasion, the presence of 
lymph node metastasis and recurrence were correlated 
with the genetic profile.
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Detection of fusion transcripts by standard RT-PCR
All the samples were screened for the presence of ETV6–
NTRK3, STRN–ALK and AGK–BRAF by standard RT-PCR. 
For the detection of fusion transcripts, primers were 
designed within exons located near the breakpoint regions 
described in PTC (Fig. 1 and Table 1).
Total RNA was isolated from the core of the tumor 
(in an attempt to avoid contamination with normal 
tissue) using Trizol (Invitrogen, Thermo Fisher Scientific), 
according to the manufacturer’s instructions. Total 
RNA concentration and purity were analyzed using a 
Nanodrop ND-2000 spectrophotometer (Thermo Fisher 
Scientific). RNA integrity was evaluated using agarose 
gel electrophoresis or Agilent 2100 Bioanalyzer System 
(Agilent Technologies). Total RNA (1 µg) was treated 
with DNAse and reverse-transcribed into cDNA with 
oligo-dT12–18 (0.5 µg) using a Superscript III reverse 
transcriptase kit (Invitrogen) as described (18). An aliquot 
of cDNA (1 µL) was subjected to PCR amplification using 
10 mM Tris–HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 
200 μM of each dNTP, 1 unit of Platinum Taq DNA 
polymerase (Invitrogen) and 200 nM of each specific 
primer for the target genes or reference gene (RPS8). PCR 
reaction was performed as follows: initial denaturation 
at 95°C for 5 min followed by 40 cycles of 95°C for 30 s, 
annealing temperature for 30 s and 72°C for 30 s, followed 
by a final extension of 72°C for 2 min. The PCR products 
were analyzed by electrophoresis on a 2% agarose gel 
and visualized on a Bio-Rad Gel Doc EZ system (Bio-Rad 
Laboratories). The presence of the fusion transcripts was 
confirmed by direct sequencing of PCR products using the 
BigDye Terminator Cycle Sequencing Kit (Thermo Fisher 
Scientific) as previously described (19). The primers used 
to detect fusions, reference gene, annealing temperatures 
and expected PCR product sizes are detailed in Table 1.
Expression of fusion oncogenes in PCCL3 cell line
PCCL3 (normal follicular thyroid cells derived from Fischer 
rats) were cultured in Ham’s F12 medium supplemented 
with 5% FBS (Gibco, Thermo Fisher Scientific) and 4 
hormone-mixture including thyrotropin (1 U/mL), 
hydrocortisone (10 nM/mL), transferrin (5 µg/mL) and 
insulin (10 µg/mL) (Sigma-Aldrich). PCCL3 cells were 
transiently transfected with the expression vector pMSCV-
ETV6–NTRK3 or pLVX-AGK-BRAF-GFP, as previously 
Figure 1
Diagram of exon/intron structure of ETV6, NTRK3, STRN, ALK, AGK and BRAF genes and the fusion transcripts described in 
thyroid carcinomas. (A) ETV6 (gray; NM_001987) and NTRK3 (black; NM_002530) genes and the fusion transcripts of ETV6–NTRK3. 
ETV6–NTRK3_1 (Cosmic ID: COSF1535) and ETV6–NTRK3_2 (Cosmic ID: COSF1537) isoforms correspond to the fusion of exon 4 or 
exon 5 of ETV6 with exon 14 of NTRK3, respectively. (B) STRN (gray; NM_003162) and ALK (black; NM_004304) genes and the 
STRN–ALK fusion transcript (Cosmic ID: COSF1431). (C) AGK (gray; NM_018238) and BRAF (black; NM_004333) genes and the 
AGK–-BRAF fusion transcript. Full blocks (gray and black) represent the coding region, and empty blocks represent the 
untranslated region (UTR). The numbers refer to the exons. The arrows indicate the position of the primers used to amplify all 
fusion transcripts described in thyroid carcinomas.
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described (20). ETV6–NTRK3 and AGK–BRAF plasmids 
were kindly donated by Dr James Fagin (Memorial Sloan-
Kettering Cancer Center). The oncogene-transfected cells 
were harvested, and the total RNA was isolated using 
TRIzol Reagents (Invitrogen) and reverse-transcribed into 
cDNA using oligo(dT)12–18, as aforementioned. The cDNA 
generated from cells expressing the fusion transcripts was 
used as a positive control. For the STRN–ALK detection, an 
aliquot of cDNA from a PTC sample known to be positive 
for STRN–ALK was used as positive control.
Statistical analyses
The association between the tumor size and the type of 
genetic alteration was determined using one-way ANOVA 
test followed by Bonferroni’s post hoc test. To determine 
the association between the type of genetic alteration and 
the clinical–pathological features, Fisher’s exact test was 
used with the raw data, and the percentage was shown 
in the graphics. Statistical analyses were performed using 
GraphPad Prism v5.01 Software (GraphPad Software).
Results
ETV6–NTRK3 was exclusively found in follicular 
variants of PTC
As two isoforms of ETV6–NTRK3 were previously 
identified in PTC (13), the set of primers used in this 
study were designed to detect both isoforms (Fig. 1 and 
Table  1). Overall, the ETV6–NTRK3 fusion transcript 
was found in 5% (n = 6) of PTC cases. All positive cases 
harbor an in-frame fusion of exon 4 of ETV6 to exon 14 
of NTRK3 (Fig. 2A and Table 2). Remarkably, ETV6–NTRK3 
was exclusively found in FVPTC, leading to a prevalence 
of about 13% (6/45) in this variant (Table 3). Essentially, 
50% were infiltrative follicular variants of papillary 
thyroid carcinoma (IFVPTC) and 50% were encapsulated 
follicular variants of papillary thyroid carcinoma 
(EFVPTC) (Table  3). One IFVPTC patient, a 23-year-old 
female, had lymph node metastasis tissue available and, 
therefore, it was also screened for the presence of ETV6–
NTRK3 transcript. The metastatic lymph node tested 
was also positive for the ETV6–NTRK3 fusion transcript 
(Fig. 2B). Although non-invasive EFVPTC have very low 
risk of adverse outcome and were recently reclassified as 
non-invasive follicular thyroid neoplasia with papillary-
like nuclear features (NIFTP), no additional tumor slides 
and blocks were available to further re-evaluate whether 
tumors are either NIFTP or invasive EFVPTC.
STRN–ALK was detected in about 3% of PTC samples
The STRN–ALK fusion transcript was found in about 3% 
(n = 4) of PTC samples (Fig.  2C, Tables  2 and 3). All the 
fusions found were in accordance with the breakpoint 
already described, corresponding to the in-frame fusion 
of exon 3 of STRN with exon 20 of ALK (Fig.  2C). The 
fusion was found in both classical and follicular variants 
of PTC (Table 3).
No AGK–BRAF was detected in this series of PTC
Samples were also examined for AGK–BRAF fusion 
transcript. No PTC case was found to be positive for AGK–
BRAF (data not shown), suggesting that AGK–BRAF fusion 
is mainly associated with pediatric PTC.
ETV6–NTRK3, STRN–ALK and AGK–BRAF are restricted 
to PTC
Since most of the fusions were found in FVPTC (78%; 
7/9) and as its molecular profile seems to be closer to the 
FTA/FTC group, the prevalence of ETV6–NTRK3, STRN–
ALK and AGK–BRAF was also investigated in a series of 
FTA (n = 22) and FTC (n = 19). The evaluated FTC and FTA 
Table 1 PCR primers, annealing temperatures and expected PCR product sizes.
Gene fusions Primer sequence (5′–3′) Temp (°C) Location Expected product size (bp)
ETV6–NTRK3a F: ACACACACAGCCGGAGGTCATAC
R: AGTGGGCTGGCTGAGTCCTCC
60 Exon 4
Exon 14
90/636b
STRN–ALK F: GCAACCTTATCCGACTTCTAGC
R: GATACTGGTGCCCGCTCTC
61 Exon 3
Exon 20
228
AGK–BRAFa F: CTGCTGACCTGGGGAGGCCATT
R: TCATCTGCTGGTCGGAAGGGCTG
60 Exon 2
Exon 8
118
RPS8 F: AACAAGAAATACCGTGCCC
R: GTACGAACCAGCTCGTTATTAG
60 Exon 3
Exon 4
104 
aRicarte-Filho et al. (15); bproduct sizes for both ETV6-NTRK3_1 (90 bp) and ETV6-NTRK3_2 (636 bp).
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samples were negative for these 3 fusions, endorsing that 
they are specifically associated with PTC subtype.
Gene fusions are found in younger patients and are 
not associated with aggressive characteristics
When samples were divided based on the presence of ETV6–
NTRK3 or STRN–ALK, there was no statistically significant 
association between with clinico–pathological parameters 
and the presence of NTRK3 or ALK fusions. When samples 
with ETV6–NTRK3 and STRN–ALK fusions were pooled 
together with those samples who harbor RET/PTC fusions 
(21) and compared with samples harboring BRAF V600E 
(19) or NRAS Q61 (21) point mutations or samples that 
were tested negative for fusions and mutations, we found 
that fusions were more common in younger patients 
(<45  years old; mean age 36.8 ± 10.0) than mutations 
(<45  years old; mean age: 41.7 ± 12.3). The difference 
was statistically significant when compared to samples 
that bear neither mutations nor fusions (<45  years old; 
mean: 52.2 ± 14.1; P < 0.01) (Fig.  3A and B). Samples 
harboring point mutations have a more aggressive 
behavior than samples negative for mutations (Fig. 3C).
Discussion
The comprehensive analysis of the mutational landscape 
of PTC (12, 22) has provided insights into the molecular 
alterations that drive its carcinogenesis. Transcriptome 
sequencing has been particularly useful in helping to 
identify novel fusions. However, an important question 
concerns the clinical impact of the found fusions: Are 
these novel fusions recurrent across multiple patients, 
tumor subtypes and populations and, therefore, provide 
the chance to improve the preoperative diagnosis of 
thyroid nodules and risk stratification?
In this study, we found that the novel fusions ETV6–
NTRK3 and STRN–ALK (12) are recurrent in this series of 
PTC from a different geographic area, while they are not 
Figure 2
Fusion transcripts detected in sporadic PTCs. (A) ETV6–NTRK3 fusion transcript identified in sporadic PTCs by standard RT-PCR. 
Positive (lanes 1 and 2) and negative (lanes 3, 4 and 5) PTC samples are shown. (B) ETV6–NTRK3 fusion transcript in a primary 
metastatic tumor (Tu) and its matched lymph node metastasis (Ln). (C) STRN–ALK fusion transcript in a sample positive (lane 2) 
and sample negative (lanes 1, 3, 4 and 5). PCR products submitted to Sanger sequencing to confirm the presence of the fusions. 
Positive (C+) and negative controls (C−) were included in each run.
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present in benign lesions and, therefore, may have an 
important impact on the diagnosis of thyroid nodules in 
adult population from different populations. AGK-BRAF, 
on the other hand, is not found in adult population 
and could have an important impact only in PTC from 
pediatric population. Whether they might have impact 
on the prognosis, it is still not clear.
Regarding NTRK3 fusions, although several 5′ partners 
were detected in PTC, the majority of them were present 
in only one sample (12). Interestingly, the ETV6–NTRK3 
Table 2 Prevalence of fusion in radiation-induced and sporadic PTC.
Reference Samples ETV6–NTRK3, n (%) STRN–ALK, n (%) AGK–BRAF, n (%)
Radiation-induced PTC
  (15)a 26 2 (8%) NE 1 (4%)
  (17)b 62 9 (14%) NE NE
  (31)c 67 4 (6%) NE NE
  Total 155 15/155 (10%) NE 1/26 (4%)
Sporadic PTC
 Pediatric     
  (15)a 27 2 (7%) NE 0 (0%)
  (16)a 30 NE NE 3 (10%)
  (32)a 17 3 (18%) NE NE
  (33)a 28 5 (18%) NE NE
  (28)d 9 0 (0%) 1 (11%) 0 (0%)
 Adult     
  (34) 20 1 (5%) 0 (0%) 0 (0%)
  (17) 151 3 (2%) NE NE
  (14) 256e NE 3 (1%) NE
  (13) 29 NE 2 (7%) NE
  (12) 496 5 (1%) 1 (0.2%) 1 (0.2%)
  (21) 125 6 (5%) 1 (1%) 0 (0%)
  (28)d 32 1 (3%) 0 0
  This study 116 6 (5%) 4 (3%) 0 (0%)
 Adult and pediatric     
  (27) 262 NE 2 (0.7%)f NE
  Total  32/1021 (3%) 14/1345 (1%) 4/855 (0.5%)
aStudies performed in samples of pediatric patients with <18 years; bstudy performed in patients who were aged <18 years at the time of Chernobyl 
accident; cstudy performed only with young adult patient samples (<22 years old); din this study, only patients <40 years old (n = 41) were further 
elucidated. The data shown in this table are only from these patients. No data about fusion partners from patients >40 years old (n = 303) were available 
in the article; ein this study, samples were classified as differentiated thyroid carcinomas; finformation about age was not available. STRN–ALK fusion was 
observed in one pediatric patient (13 years old) and in one adult patient (50 years old).
NE, not evaluated.
Table 3 The demographic and clinico–pathological features of PTCs positive for ETV6–NTRK3 and STRN–ALK fusions.
ID Sex Age (years) Size (cm) Histological variant Multifocality ETE LNM Recurrence
ETV6–NTRK3         
 1a F 43 2.5 IFVPTC No No No No
 2 M 23 2.5 IFVPTC Yes Yes Yesb Yes
 3 F 31 NA EFVPTC No NA No No
 4 F 48 2.8 EFVPTC No No No No
 5 F 42 2.0 IFVPTC Yes Yes No NA
 6 F NA 3.0 EFVPTC No No No No
STRN–ALK
 1a F 43 2.5 IFVPTC No No No No
 7 F 43 3.5 FVPTCc No No No No
 8 F 47 1.5 Classical Yes Yes No No
 9 M 34 2.2 Classical Yes No Yes No
aPatient 1 was positive for both ETV6–NTRK3 and STRN–ALK, and also for RET/PTC2 (30); blymph node metastasis from patient 2 was also positive for 
ETV6–NTRK3; cinformation regarding the presence/absence of capsule is not available.
ETE, extrathyroidal extension; LNM, lymph node metastasis; F, female; M, male; NA, not available; IFVPTC, infiltrative (non-encapsulated) follicular 
variant of papillary thyroid carcinoma; EFVPTC, encapsulated follicular variant of papillary thyroid carcinoma.
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fusion was identified as a common event in PTCs from 
patients who were exposed to radiation (15), and was 
also reported in sporadic pediatric (13) and adult PTCs 
(15). Afterward, it has been confirmed that ETV6–NTRK3 
is a recurrent event in PTC (12, 22) and is also able to 
induce MAPK activation and promote cell growth and 
transformation (13). Two ETV6–NTRK3 isoforms have 
been identified in thyroid samples (15). Most of the 
fusions reported involve exon 4 of ETV6 and exon 14 of 
NTRK3, but one case involved fusion of exon 5 of ETV6 
and exon 14 of NTRK3 (13). Therefore, we investigated 
the prevalence of ETV6–NTRK3 fusion in a large set of 
sporadic PTCs, using a set of primers that would allow us 
to detect both isoforms. We here identified ETV6–NTRK3 
in six PTC cases. The prevalence (5%) is slightly higher 
than previously reported in adults but still lower than 
that reported in radiation-exposed PTC. Remarkably, all 
ETV6–NTRK3-positive cases were from FVPTC.
FVPTC is recognized as a tumor composed of 
follicles rather than papillae, but with cells presenting 
the nuclear features of PTC, and can be further divided 
into infiltrative (IFVPTC) or encapsulated (EFVPTC). It 
has been suggested that infiltrative tumors were more 
likely to have extrathyroidal extension and lymph node 
metastases, and its biological behaviors are similar to the 
conventional PTC, while the encapsulated behaves more 
like follicular thyroid tumors. At the molecular levels, it 
has been suggested that the non-invasive EFVPTC have a 
high prevalence of mutations that are usually associated 
with follicular-patterned thyroid tumors such as FTA and 
FTC (22, 23, 24). As we found ETV6–NTRK3 fusion in three 
EFVPTC, we tested whether other follicular-patterned 
lesions, such as the benign FTAs and the malignant FTCs, 
could harbor ETV6–NTRK3 fusion. None of the benign 
FTAs or malignant FTCs were positive for ETV6–NTRK3. 
Therefore, ETV6–NTRK3 fusion has the potential to serve 
as a diagnostic marker for FVPTC. Since FVPTC represents 
a diagnostic challenge on fine-needle aspiration cytology 
and the percentage of follicular-patterned thyroid 
malignancies that proved to be FVPTC on final biopsy 
has increased, these findings have important clinical 
implications.
Regarding the prognostic implications, most ETV6–
NTRK3-positive cases were under the age of 45  years, 
two cases had extrathyroidal extension and one case had 
lymph node metastasis. When both the paired primary 
tumor and the lymph node metastases were profiled, the 
ETV6–NTRK3 fusion was also found in the lymph node 
metastases. The fact that this fusion was found in IFVPTC, 
as well as in the paired lymph node metastases, raises the 
possibility that tumors with ETV6–NTRK3 fusion might 
have the potential to metastasize. However, whether 
additional mutations are needed to tumor progression, 
we still do not know.
Although ALK fusions are rare in thyroid cancer, 
aberrant ALK activation due to rearrangements leads to 
constitutive activation of the MAPK pathway in both PTC 
(16) and other tumor subtypes (25, 26). While originally 
found in PTC with more advanced stage of disease and 
tumors prone to dedifferentiation (16), STKN–ALK fusion 
has also been described in classical PTC (17, 22). Although 
other ALK fusion was described in medullary thyroid 
carcinoma (MTC) (27), STKN–ALK fusion was not found 
in FTC and MTC (16). In our cohort, four PTCs exhibited 
the STRN–ALK fusion. Although no association was found 
with demographic and clinico–pathological features such 
as histological subtypes, age and aggressiveness, one of 
the four PTC samples positive for STRN–ALK had lymph 
Figure 3
PTC samples divided into 3 groups according to the mutational status. Fusions: PTC samples with ETV6–NTRK3, STRN–ALK and 
RET/PTC (21) fusions. Mutations: PTC samples with point mutations in BRAF gene (19) or NRAS (21). Negative: those who bear 
neither fusions nor mutations. (A) Patients were classified according to age (≤45 vs >45 years old). Fusions were more prevalent 
in younger patients than negative. (B) Mean age of diagnosis of patients harboring fusions (age 36.8 ± 10.0), mutations 
(41.7 ± 12.3) or negative (mean: 52.2 ± 14.1). (C) Percentage of patients with the presence of metastasis, extrathyroidal extension 
and risk of recurrence in each group (fusion, mutation and negative). *P < 0.05; **P < 0.01.
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node metastasis at diagnosis. Interestingly, the STRN–
ALK fusions found in pediatric PTCs were metastatic or 
of a solid variant, indicating its association with a more 
aggressive phenotype even in pediatric samples (28, 29).
Importantly, the ALK inhibitor, crizotinib, has been 
shown to be effective in the treatment of patients with 
thyroid tumors harboring STRN–ALK (30) or other ALK 
fusions (27). A more detailed understanding of the 
downstream targets these fusions affect and the cellular 
process they are involved may help to find novel 
therapeutic targets.
Although common, a wide range of different 5′ 
partners were found to be fused in-frame to BRAF, and 
most were non-recurrent events (12). AGK–BRAF was 
found as a recurrent event in sporadic pediatric PTC 
samples (14) and in one radiation-exposed PTC case (13); 
however, in the TCGA cohort, only one PTC exhibited 
AGK–BRAF fusion. No AGK–BRAF fusion was found in 
over 100 adult-sporadic PTCs, endorsing that AGK–BRAF 
is an event likely associated with PTCs of younger age, 
while BRAF V600E is the leading genetic event in adult-
sporadic PTC (12, 22).
Finally, nearly 26% (30/116) of all PTC samples in 
this cohort are negative for the most prevalent events 
described in PTC (19, 21).
The integrated view of RET/PTC fusions previously 
reported in this cohort (21), and those reported here, 
supports that these kinase fusions are recurrent events 
in PTC. Additionally, fusions were more prevalent in 
younger patients (<45 years old), while point mutations 
were associated with a more aggressive tumor phenotype. 
The identification of these fusions in thyroid carcinomas 
not only helps to expand our knowledge about the 
landscape of PTC but it also suggests that ETV6–NTRK3 
and STRN–ALK are useful for screening and therapeutic 
targets. Further analysis is still needed to delineate the 
comprehensive panorama of PTC.
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